Patents Represented by Attorney Robert J. North
  • Patent number: 4914220
    Abstract: A process is described for the synthesis of E-2-methyl-.alpha.,.beta.-unsaturated aldehydes, which are useful as intermediates in the synthesis of the macrolide structure of the immunosuppressant FK-506. These compounds are also useful as ultraviolet radiation absorbers.
    Type: Grant
    Filed: February 27, 1989
    Date of Patent: April 3, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Richard Desmond, Sander G. Mills, Ralph P. Volante, Ichiro Shinkai
  • Patent number: 4904672
    Abstract: 3-Hydroxyazabenzo[b]thiophene derivatives having optionally 2-aryl, 2-aralkyl, 2-alkyl or 2-alkenyl substituents were prepared by, among other methods, ring closure of an appropriately substituted benzylthioalkoxycarbonyl-pyridine. These compounds are found to be useful in the treatment of pain, fever, inflammation, arthritic conditions, asthma, allergic disorders, skin diseases such as psoriasis and atopic eczema, cardiovascular disorders, inflammatory disease and other leukotriene mediated diseases.
    Type: Grant
    Filed: April 28, 1988
    Date of Patent: February 27, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Kathleen M. Rupprecht, Arsenio A. Pessolano, Philippe L. Durette
  • Patent number: 4892869
    Abstract: Disclosed are 2-aza-substituted 1-carbadethiapen-2-em-3-carboxylic acids I, where the generic 2-aza group includes azido, acylamino, amino, alkylamino, dialkylamino, triazolyl, triazolinyl, aziridinyl, and their pharmaceutically acceptable salt, ester, anhydride and amide derivatives which are useful as antibiotics. Also disclosed are processes for the preparation of 1 from the known, appropriately substituted bicyclic keto ester II via the 2-azido central intermediate III: ##STR1## wherein R.sup.16 is H or CH.sub.3, preferably beta-methyl; R.sup.6, and R.sup.7 are independently hydrogen, linear, branched or cyclic C.sub.1 -C.sub.5 alkyl, which can be substituted with fluoro, hydroxy, protected hydroxy, sulfoxy, amino, protected amino, wherein R.sup.6 and R.sup.7 taken together can also be C.sub.2 -C.sub.4 alkylidene, similarly substituted; with the proviso that both R.sup.6 and R.sup.7 are not unsubstituted alkyl, R.sup.1 and R.sup.
    Type: Grant
    Filed: January 19, 1989
    Date of Patent: January 9, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Burton G. Christensen, Ronald W. Ratcliffe, John C. Chabala
  • Patent number: 4892951
    Abstract: Substituted 3-nitropyridines are disclosed to have activity in increasing the sensitivity of hypoxic tumor cells to therapeutic radiation. Also disclosed are methods of preparing such compounds by amination of the corresponding chloro-3-nitropyridine with 2,3-dihydroxypropylamine and pharmaceutical compositions including such compounds.
    Type: Grant
    Filed: November 17, 1988
    Date of Patent: January 9, 1990
    Assignee: Merck & Co., Inc.
    Inventor: Walfred S. Saari
  • Patent number: 4891370
    Abstract: Derivatives of cephalosporin esters are found to be potent elastase inhibitors and therefore are useful antiinflammatory agents.
    Type: Grant
    Filed: December 14, 1981
    Date of Patent: January 2, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Morris Zimmerman, Bunnie M. Ashe, James B. Doherty
  • Patent number: 4885276
    Abstract: New cyclosporin analogs with modified "C-9 amino acids" have been made and are found to be effective immunosuppressive agents.
    Type: Grant
    Filed: October 24, 1988
    Date of Patent: December 5, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Bruce E. Witzel
  • Patent number: 4880793
    Abstract: A novel antibacterial drug combination is provided, one component being a 2-substituted penem, and the other component is a dipeptidase (E.C.3.4.13.11) inhibitor. The dual-component combination is formulated so that 1 to 3 parts by weight of the penem are employed for 30 to 1 parts by weight of the inhibitor compound.
    Type: Grant
    Filed: March 14, 1986
    Date of Patent: November 14, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Helmut Kropp, Frederick M. Kahan
  • Patent number: 4873324
    Abstract: Compounds are disclosed of the structural formula: ##STR1## wherein R.sup.2 is independently selected from hydrogen, linear or branched C.sub.1 -C.sub.3 alkyl, which can be substituted with fluoro, hydroxy, or protected hydroxy, R.sup.3 is hydrogen or a protecting group, X is sulfur or selenium, Q is hydroxymethyl, carboxy or C.sub.1 -C.sub.4 alkoxycarbonyl, and R.sup.1 is C.sub.1 -C.sub.4 alkyl, C.sub.6 -C.sub.10 aryl, or pyridyl which can be substituted with C.sub.1 -C.sub.4 alkyl, alkoxy and nitro; such compound are useful for selectively obtaining 1-.beta.-methylcarbapenem intermediates.
    Type: Grant
    Filed: February 6, 1989
    Date of Patent: October 10, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Burton G. Christensen, Lovji D. Cama, Susan M. Schmitt
  • Patent number: 4871873
    Abstract: A process for producing arylglyoxal arylimine intermediates, by the DMSO/HBr oxidation of arylmethylketones. The imine compounds are intermediates in the synthesis of carbapenem antibiotics, i.e. imipenem.
    Type: Grant
    Filed: March 18, 1988
    Date of Patent: October 3, 1989
    Assignee: Merck & Company Incorporated
    Inventors: Richard Desmond, Sander G. Mills, Ralph P. Volante, Ichiro Shinkai
  • Patent number: 4868155
    Abstract: Disclosed are specific dipeptidyl 4-0, 6-0-acyl-2-amino-2-deoxy-D-glucose derivatives which, either alone, or in combination with an anti-AIDS drug, e.g. azidothymidine, protect against opportunistic bacterial, fungal and viral infection in a human host immunocompromised by an AIDS-related virus, as well as help to suppress the AIDS-related virus itself.
    Type: Grant
    Filed: October 5, 1987
    Date of Patent: September 19, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, Conrad P. Dorn
  • Patent number: 4868157
    Abstract: Disclosed are specific dipeptidyl 2-amino-1,2-dideoxy-D-glucoses which, either alone, or in combintion with an anti-AIDS drug, e.g. azidothymidine, protect an immunocompromised human host, resulting from an AIDS-related virus, against opportunistic, bacterial, fungal and viral infections, as well as help to suppress the AIDS-related virus itself.
    Type: Grant
    Filed: October 5, 1987
    Date of Patent: September 19, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Philippe L. Durette
  • Patent number: 4866035
    Abstract: Disclosed are specific dipeptidyl saccharide derivatives which alone, or in combination with an anti-AIDS drug, e.g. azidothymidine, provide protection against opportunistic infection in human individuals whose resistance to infection has been specifically suppressed by an AIDS-related (HIV) virus, as well as help to suppress the AIDS-related infection itself.
    Type: Grant
    Filed: October 5, 1987
    Date of Patent: September 12, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Philippe L. Durette
  • Patent number: 4866036
    Abstract: Disclosed are specific dipeptidyl 5-0, 6-0-Acyl-2-amino-2-deoxy-D-glucofuranoses, which, either alone, or in combination with an anti-AIDS drug, e.g. azidothymidine, provide protection in human individuals whose resistance to infection has been specifically suppressed by an AIDS-related (HIV) virus, as well as help to suppress the AIDS-related infection itself.
    Type: Grant
    Filed: October 5, 1987
    Date of Patent: September 12, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Philippe L. Durette
  • Patent number: 4839352
    Abstract: Disclosed are N-acyl derivatives of the antibiotic thienamycin having the following structural formula: ##STR1## wherein R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen and acyl. Such derivatives and their pharmaceutically acceptable salts, are useful as antibiotics. Also disclosed are processes for the preparation of such derivatives, pharmaceutical compositions comprising such derivatives, and methods of treatment comprising administering such derivatives and compositions when an antibiotic effect is indicated.
    Type: Grant
    Filed: August 27, 1987
    Date of Patent: June 13, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Louis Barash, Burton G. Christensen, John Hannah, William J. Leanza, David H. Shih
  • Patent number: 4835177
    Abstract: Disclosed are specific aminoalkyl naphthalenediol derivatives that enhance natural human host resistance to viral infectious organisms and particularly AIDS-related viruses. Such agents are also administered prophylactically to individuals whose resistance to infection has been specifically immunocompromised by an AIDS-related (HIV) virus.
    Type: Grant
    Filed: June 11, 1987
    Date of Patent: May 30, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Philipe L. Durette
  • Patent number: 4833167
    Abstract: Disclosed are 2-aza-substituted 1-carbadethiapen-2-em-3-carboxylic acids I, where the generic 2-aza group includes azido, acylamino, amino, alkylamino, diaklylamino, triazolyl, triazolinyl, aziridinyl, and their pharmaceutically acceptable salt, ester, anhydride and amide derivatives which are useful as antibiotics. Also disclosed are processes for the preparation of I from the known, appropriately substituted bicyclic keto ester II via the 2-azido central intermediate III: ##STR1## wherein R.sup.16 is H or CH.sub.3, preferably beta-methyl; R.sup.6, and R.sup.7 are independently hydrogen, linear, branched or cyclic C.sub.1 -C.sub.5 alkyl, which can be substituted with fluoro, hydroxy, protected hydroxy, sulfoxy, amino, protected amino wherein R.sup.6 and R.sup.7 taken together can also be C.sub.2 -C.sub.4 alkylidene, similarly substituted; with the proviso that both R.sup.6 and R.sup.7 are not unsubstituted alkyl, R.sup.1 and R.sup.
    Type: Grant
    Filed: June 10, 1985
    Date of Patent: May 23, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Burton G. Christensen, John C. Chabala, Ronald W. Ratcliffe
  • Patent number: 4816577
    Abstract: A process for isomerizing an alpha methylated azetidinone alkyl ester to the corresponding beta-methyl isomer, which is an intermediate in the synthesis of 1-beta-methylcarbapenem antibacterial agents. The process involves treating the dianion of structure I, being the alpha isomer, with a P-H or S-H containing organic protic acid, organometallic Sn or Pb hydride, metallic cation salt or trialkyl borane, followed by quenching with an OH protic organic acid or mineral acid.
    Type: Grant
    Filed: December 16, 1987
    Date of Patent: March 28, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Dean R. Bender, Ichiro Shinkai, Anthony M. De Marco, James A. McCauley
  • Patent number: 4816578
    Abstract: A stereospecific process for preparing 3-trans-R-trisubstituted silyloxyethyl substituted azetidinones useful as intermediates for preparing penems and carbapenems is provided wherein a 3-unsubstituted azetidinone is treated with a strong base and a trisubstituted silylmethyl ketone to form 3-trans-S-[1-trisubstituted silyl-1-hydroxy]ethylazetidinone followed by rearrangement of this resulting carbinol by treatment with an alkali metal alkoxide and a proton source.
    Type: Grant
    Filed: February 26, 1988
    Date of Patent: March 28, 1989
    Assignee: Merck & Co., Inc.
    Inventors: F. Aileen Bouffard, Thomas N. Salzmann
  • Patent number: 4806680
    Abstract: Described bare 3-halovinylglycines and their amino acid dipeptide and oligopeptide conjugates, a new class of efficient antibacterial agents, pharmaceutical compositions containing them as active ingredients, and methods of synthesis. The compounds are thought to interfere in bacterial cell wall synthesis.
    Type: Grant
    Filed: November 12, 1987
    Date of Patent: February 21, 1989
    Assignee: Merck & Co., Inc.
    Inventors: David Taub, Robert H. Abeles, Arthur A. Patchet
  • Patent number: 4791207
    Abstract: A process is described for the stereochemically controlled synthesis of intermediates useful in producing 1-betamethylcarbapenem antibiotics.
    Type: Grant
    Filed: May 4, 1987
    Date of Patent: December 13, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Thomas N. Salzmann, Lelia M. Fuentes, Ichiro Shinkai